The Molecular Detection of EBV Among Hodgkin and Non-Hodgkin Lymphoma in Iraqi Patients

Authors

  • Aya Raad Saleh Department of Molecular and Medical Biotechnology, College of Biotechnology, Al-Nahrain University, IRAQ

DOI:

https://doi.org/10.55544/sjmars.4.5.10

Keywords:

Epstein–Barr Virus (EBV), Hodgkin Lymphoma, Non-Hodgkin Lymphoma

Abstract

Objective: The study amied to detect the molecular pattern of Hodgkin lymphoma and non-Hodgkin lymphoma (NHL) in Iraqi patients and identifying the most common kind of both among the female and male Iraqi patients . Epstein-Barr virus (EBV) infection is closely associated with many subtypes of malignant lymph nodes of both Hodgkin and non-Hodgkin lymphoma. Two of the most common hematological malignancies in the world are NHL and HL. Having a variety of biological and clinical characteristics, it originates from lymph tissue. Method: 359 specimens ranging in age from 25 to 75 years were gathered from the pathology departments of Al _kadhymia teaching hospital/ hematology department. Our goal was to find out how common EBV is in NHL and HL. Result: The current study included 359 specimens (186 females and 173 males), which investigated the percentage of NHL in ladies was (35.1%), whereas HL's was (64.9%) . HL with (43.2%) was detected in males, while NHL was (57.8%) ,which represent a higher differences (P≤0.0001) between NHL and HL in female and male.

References

[1] Mittal A, Bhethanabhotla S, Ganguly S, Vishnubhatla S, Khadgawat R, Patel C, Mohan A, Biswas A, Bakhshi S. Late effects in paediatricHodgkin lymphoma survivors after uniform treatment with ABVD with or without radiotherapy. Pediatr Blood Cancer. 2021;68(11):e29293.

[2] Lo AC, Dieckmann K, Pelz T, Gallop-Evans E, Engenhart-Cabillic R, Vordermark D, Kelly KM, Schwartz CL, Constine LS, Roberts K, Hodgson D. Paediatricclassical Hodgkin lymphoma. Pediatr Blood Cancer. 2021. 68 (Suppl 2):e28562

[3] Ghafoor T. Prognostic factors in paediatricHodgkin lymphoma: experience from a developing country. Leuk Lymphoma. 2020;61(2):344-350

[4] Luna-Fineman S, Castellanos M, Metzger ML, Baez LF, Hernandez AP, Bonilla M, Fuentes-Alabi S, Nieves R, Blanco J, Rossi E, Devidas M, Chen Y, Arreola M, de Alarcon PA. Treatment of high-risk Hodgkin lymphoma with a modified Stanford V regimen in the AHOPCA: Substituting chemotherapy agents and hampered outcomes. Pediatr Blood Cancer. 2023;71(2):e30792.

[5] Mahaian A, Bakhshi S, Seth R, Verma N, Mandal P, Singh M, Jain S, Radhakrishnan V, Kanvinde S, Arora RS, Dinand V, Kalra M, Taluja A, Mallick S, Kumar R, Chandra J. Hodgkin lymphoma in Children Under 5 years: Do They Behave Differently? J Pediatr Hematol Oncol. 2022;44(4):186-190.

[6] Andersson A, Enblad G, Erlanson M, Johansson A-S, Molin D, Tavelin B, Näslund U, Melin B. High risk of cardiovascular side effects after treatment of Hodgkin's lymphoma - is there a need for intervention in long-term survivors ? Ups J Med Sci. 2021;15:126.

[7] Alaswad EA, Abdul-Mohymen N, Ghazi HF. Expression of Ki67and p53 Proteins in Hodgkin׳s Lymphomas and Non Hodgkin׳s Lymphoma patients using immunohistochemistry. Iraqi Cancer and Medical Genetics 2011; 4: 37-42

[8] Ozer H, Yenicesu G, Arici S, Cetin M, Tuncer E, Cetin A. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagnostic Pathol2012; 7: 124

[9] Mishra SK, Crasta JA. An immunohistochemical comparison of P53 and Bcl-2 as apoptotic and MIB1 as proliferative markers in low-grade and high-grade ovarian serous carcinomas. Int J Gynecol Cancer2010; 20(4): 537-41

[10] Alaswad EA, Abdul-Mohymen N, Ghazi HF. Expression of Ki67and p53 Proteins in Hodgkin׳s Lymphomas and Non Hodgkin׳s Lymphoma patients using immunohistochemistry. Iraqi Cancer and Medical Genetics 2011; 4: 37-42.

[11] Yang QP, Zhang WY, Yu JB, Zhao S, Xu H, Wang WY. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011;6:77.

[12] Syed S, Khalil S, Pervez S. Anaplastic large cell lymphoma: the most common T-cell lymphoma in Pakistan. Asian Pac J Cancer Prev. 2011;12:685–9.

[13] Bo W, Mei K, Zhaoming W, Hongtian Y, Yanfeng B, Xiaoying N. CD79a positive T cell lymphoma with bone marrow involvement. Pathology 2011;43:737–40.

[14] Wang E, Stoecker M. Primary mediastinal (thymic) large B cell lymphoma with aberrant expression of CD3: a case report with review of the literature. Int J Hematol. 2010;91:509–15.

[15] yengar, P., Mazloom, A., Shihadeh, F., Berjawi, G., & Dabaja, B. (2010). Hodgkin lymphoma involving extranodal and nodal head and neck sites: characteristics and outcomes. Cancer, 116(16), 3825–3829.

[16] Shahid, R., Gulzar, R., Avesi, L., Hassan, S., Danish, F., & Mirza, T. (2016). Immunohistochemical Profile of Hodgkin and Non-Hodgkin Lymphoma. J Coll Physicians Surg Pak, 26(2), 103–107

[17] Campos AHJFM, Moreira A, Ribeiro KB, Paes RP, Zerbini MC, Aldred V, et al. Frequency of EBV associated classical Hodgkin Lymphoma decreases over a 54-year period in a Brazilian population. Scientific reports. 2018; 8: 1849.

[18] Shenoy P, Maggioncalda A, Malik N, Flowers CR. Incidence Patterns and Outcomes for Hodgkin Lymphoma Patients in the United States. Advances in Hematology. 2011; 2011; Article ID 725219, 11 pages.

[19] Shamoon RP, Ali MD, ShabilaNP. Overview and outcome of Hodgkin's lymphoma:Experience of a single developing country oncology centre. PLoS One. 2018; 13(4): e0195629.

[20] Al-Mudallal SS, Al-Sinjery GM. Immunohistochemical expression of Epstein Barr virus antigen latent membrane protein-1 and Bcl-2 in classical Hodgkin lymphoma. Iraqi J Med Sci. 2012; 10(3): 234-242

[21] Yaqo RT, Hughson MD, Sulayani FK, Al-Allawi NA. Malignant lymphoma in northern Iraq: A retrospective analysis of 270 cases according to the World Health Organization classification. Indian J Cancer. 2011; 48(4): 446-51

[22] Flerlage JE, Hiniker SM, Armenian S, Benya EC, Bobbey AJ, Chang V, Cooper S, Coulter DW, Cuglievan B, Hoppe BS, Isenalumbe L, Kelly K, Kersun L, Lamble AJ, Larrier NA, Magee J, Oduro K, Pacheco M, Price AP, Roberts KB, Smith CM, Sohani AR, Trovillion EM, Walling E, Xavier AC, Burns JL, Campbell M. PaediatricHodgkin Lymphoma, Version 3.2021. J Natl Compr Canc Netw. 2021;19(6):733-754

[23] Jain S, Kapoor G, Bajpai R. ABVD-based Therapy for Hogkin Lymphoma in Children and Adolescents: lessons Learnt in a Tertiary Care Oncology Center in a Developing Country. Pediatr Blood Cancer. 2016;63:1024-1030.

Downloads

Published

2025-10-26

How to Cite

Saleh, A. R. (2025). The Molecular Detection of EBV Among Hodgkin and Non-Hodgkin Lymphoma in Iraqi Patients. Stallion Journal for Multidisciplinary Associated Research Studies, 4(5), 72–75. https://doi.org/10.55544/sjmars.4.5.10

Issue

Vol. 4 No. 5 (2025): October Issue

Section

Articles

License

Copyright (c) 2025 Stallion Journal for Multidisciplinary Associated Research Studies

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.